SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases.
Company Details
- Employees
- 19
- Founded
- -
- Address
- Am Klopfspitz 19, Martinsried,82152,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.scirhom.com
- HQ
- Martinsried
Scirhom Questions
Scirhom's website is http://www.scirhom.com
Scirhom's LinkedIn profile is https://de.linkedin.com/company/scirhom
Scirhom has
19 employees.
View email and phone details for 19
employees at Scirhom.
Scirhom's industry is
Biotechnology Research
Scirhom's top competitors are
Tubulis Gmbh,
Coriolis Pharma,
Invitris,
Eisbach Bio Gmbh,
Ethris,
Medigene Ag,
Catalym Gmbh,
Ariceum Therapeutics,
Proteros Biostructures Gmbh,
Iomx Therapeutics Ag.
Scirhom's categories are Biotechnology Research
Scirhom's founding year is 2016
